Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements
Recruiting · NCT07599696 · Interventional (participants receive a specific treatment) · Lead sponsor: Michigan State University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease. By characterizing the acoustic and perceptual effects of speech amplification and identifying ways to optimize outcomes through talker- and device-specific enhancements, this project seeks to develop personalized, evidence-based treatment options for hypophonia. The current proposal will move this effort forward by systematically eliciting and modifying speech amplification device output that leverage both behavioral and technological approaches.
Who can take part
Inclusion criteria
- Dominant speakers of North American English
- Have received a neurologist's diagnosis of Parkinson disease or parkinsonism (e.g., PSP/MSA/PSP)
- Present with changes in their speech/voice
Exclusion criteria
- History of any other speech, language, or neurological concern other than Parkinson/parkinsonism.
- Uncorrected hearing loss that exceeds a threshold of 40 dB HL in more than one ear (as per baseline screening audiometry) and/or use of a cochlear implant.
Where it is running
1 location listed across 1 US state.
- Michigan State University - East Lansing, Michigan, United States